Propantheline

drug

On this page

Also known as Propantheline cationPropantheline ionSID11111683SID11112101SID90340675PROPANTHELINE BROMIDE

Summary

Propantheline (CHEMBL1180725) is an approved small molecule (ATC A03AB05) targeting CHRM1, CHRM2, and CHRM3; indicated across 1 condition.

At a glance

Status: Approved (max clinical phase 4)
Modality: Small molecule
ATC class: A03AB05
Targets: 4 (CHRM1, CHRM2, CHRM3…)
Indications: 1 condition
Clinical trials: 1
Chemistry: 368.5 Da · C23H30NO3+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1180725
Name	Propantheline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4934
ATC	A03AB05
Molecular formula	C23H30NO3+
Molecular weight	368.5
InChIKey	VVWYOYDLCMFIEM-UHFFFAOYSA-N

SMILES: CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C

IUPAC name: methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium

Also known as: Propantheline, Propantheline cation, Propantheline ion, SID11111683, SID11112101, SID90340675, propantheline, PROPANTHELINE, PROPANTHELINE BROMIDE

Parent form; salt/anhydrous children: CHEMBL1240

Patent coverage: 1,487 distinct patent families (5,428 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CHRM1	M₁ receptor	Antagonist	9.7	0.2%	P11229
CHRM2	M₂ receptor	Antagonist	9.5	0%	P08172
CHRM3	M₃ receptor	Antagonist	10	0%	P20309
CHRM4	M₄ receptor	Antagonist	10.2	1.6%	P08173

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Thyrotropin receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M1, Cytochrome P450 2D6, Nuclear factor NF-kappa-B p105 subunit, Cytochrome P450 1A2, Cytochrome P450 3A4.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 17 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P08482	9	Potency	1	nM	CHEMBL_ACT_4857914
CHRM2	8.52	AC50	3	nM	CHEMBL_ACT_25195995
CHRM1	8.52	AC50	3	nM	CHEMBL_ACT_25210427
P08482	7.95	Potency	11.2	nM	CHEMBL_ACT_4811384
CYP2D6	5.9	Potency	1259	nM	CHEMBL_ACT_4994200
CYP2D6	5.9	AC50	1259	nM	CHEMBL_ACT_6041817
KCNH2	5.7	AC50	2000	nM	CHEMBL_ACT_25118127
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_3941243
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_4751413

Target pathways

Aggregated over 4 target gene(s): CHRM1, CHRM2, CHRM3, CHRM4.

Top Reactome pathways

17 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	4	CHRM1, CHRM2, CHRM3, CHRM4
Signaling by GPCR	4	CHRM1, CHRM2, CHRM3, CHRM4
Class A/1 (Rhodopsin-like receptors)	4	CHRM1, CHRM2, CHRM3, CHRM4
Amine ligand-binding receptors	4	CHRM1, CHRM2, CHRM3, CHRM4
GPCR downstream signalling	4	CHRM1, CHRM2, CHRM3, CHRM4
Muscarinic acetylcholine receptors	4	CHRM1, CHRM2, CHRM3, CHRM4
GPCR ligand binding	4	CHRM1, CHRM2, CHRM3, CHRM4
G alpha (q) signalling events	2	CHRM1, CHRM3
G alpha (i) signalling events	2	CHRM2, CHRM4
Metabolism	1	CHRM3
Integration of energy metabolism	1	CHRM3
Membrane Trafficking	1	CHRM2
Acetylcholine regulates insulin secretion	1	CHRM3
Regulation of insulin secretion	1	CHRM3
Vesicle-mediated transport	1	CHRM2
Cargo recognition for clathrin-mediated endocytosis	1	CHRM2
Clathrin-mediated endocytosis	1	CHRM2

Dominant GO biological processes

GO term	Targets
signal transduction	4
G protein-coupled receptor signaling pathway	4
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	4
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	4
G protein-coupled acetylcholine receptor signaling pathway	4
chemical synaptic transmission	4
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	3
nervous system development	3
regulation of locomotion	2
saliva secretion	2
acetylcholine receptor signaling pathway	2
regulation of smooth muscle contraction	2
phospholipase C-activating G protein-coupled receptor signaling pathway	1
neuromuscular synaptic transmission	1
positive regulation of monoatomic ion transport	1

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01640002	PHASE1	UNKNOWN	A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

566 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
ACLIDINIUM BROMIDE	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
Mavorixafor	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
ACETYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
AMIODARONE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
AMOXAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
ATROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
BENZTROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
BETHANECHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
BIPERIDEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CARBACHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CARBAMOYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CEVIMELINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CHLOROQUINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CINNARIZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CLEMASTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CLIDINIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CLOZAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CYCLIZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
DARIFENACIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
DESLORATADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
DICYCLOMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
DIMENHYDRINATE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
DIPHENIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
DOXEPIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
EBASTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
ECONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
GLYCOPYRRONIUM BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
HALOPERIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
HOMATROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
HYDROXYCHLOROQUINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
IMIPRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
IPRATROPIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
KETOTIFEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
LOXAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
MAPROTILINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
MEPAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
METHSCOPOLAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
METHSCOPOLAMINE BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
MIANSERIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
MICONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
OLANZAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
ORPHENADRINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
OXYBUTYNIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
PAROXETINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
PERHEXILINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
PILOCARPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
PIRENZEPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
PROMAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
PROMETHAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
QUETIAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
QUINACRINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
RISPERIDONE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
SCOPOLAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
SERTRALINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
SOLIFENACIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
SULOCTIDIL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
TAMOXIFEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
TERCONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
THIORIDAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
TIOTROPIUM BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
TOLTERODINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
TRIHEXYPHENIDYL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
TROPICAMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
TROSPIUM CHLORIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
XANOMELINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
BLARCAMESINE	ChEMBL	Phase 3	CHRM1, CHRM2, CHRM3, CHRM4
DIMETHINDENE	ChEMBL	Phase 3	CHRM1, CHRM2, CHRM3, CHRM4
ENCLOMIPHENE	ChEMBL	Phase 3	CHRM1, CHRM2, CHRM3, CHRM4
ABAPERIDONE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
APROFENE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
BENZETHONIUM CHLORIDE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
FLUNARIZINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
METHYLBENACTYZIUM BROMIDE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
OTENZEPAD	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
PF-03635659	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
SABCOMELINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
TALSACLIDINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
ZOTEPINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
chenodiol	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
LINAGLIPTIN	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
AMBENONIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
ANISOTROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
BENPERIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
BETAMETHASONE PHOSPHORIC ACID	ChEMBL	Phase 4 (approved)	CHRM1, CHRM3, CHRM4
CARIPRAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM4
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3

Genes: CHRM1, CHRM2, CHRM3, CHRM4
Drugs: Aclidinium Bromide, Mavorixafor, Acetylcholine, Amiodarone, Amitriptyline, Amoxapine, Astemizole, Atropine, Benztropine, Bethanechol, Biperiden, Carbachol, Cevimeline, Chloroquine, Chlorpromazine, Cinnarizine, Clemastine, Clidinium, Clomipramine, Clotrimazole, Clozapine, Cyclizine, Cyproheptadine, Darifenacin, Desloratadine, Dexchlorpheniramine, Dicyclomine, Dimenhydrinate, Diphenhydramine, Diphenidol, Doxepin, Ebastine, Econazole, Fluphenazine, Glycopyrronium Bromide, Haloperidol, Homatropine, Hydroxychloroquine, Imipramine, Ipratropium, Ketotifen, Loxapine, Maprotiline, Mepazine, Methscopolamine, Mianserin, Miconazole, Nortriptyline, Olanzapine, Orphenadrine, Oxybutynin, Paroxetine, Perhexiline, Pilocarpine, Pirenzepine, Prochlorperazine, Promazine, Promethazine, Quetiapine, Quinacrine, Risperidone, Scopolamine, Sertraline, Solifenacin, Suloctidil, Tamoxifen, Terconazole, Thioridazine, Tiotropium Bromide, Tolterodine, Trihexyphenidyl, Tropicamide, Xanomeline, Blarcamesine, Dimethindene, Enclomiphene, Afatinib, chenodiol, Linagliptin, Propoxyphene, Ambenonium, Anisotropine, Benperidol, Betamethasone Phosphoric Acid, Cariprazine, Cyclobenzaprine

Summary

Identifiers

Drug identity and classification

Targets

Targets

Bioactivity

Target pathways

Top Reactome pathways

Dominant GO biological processes

Indications & clinical

Indications

Clinical trials

Phase distribution

Top trials by phase / activity

Clinical evidence (CIViC)

Pharmacology

Pharmacogenomics

Related molecules

Related molecules

Related Atlas pages